Why the study?
Although serum amyloid A and S100 proteins are biomarkers of interest for rheumatoid arthritis, the clinical relevance of specific SAA allelic variants was not established.
Do plasma levels of SAA variants and S100A8/S100A9 proteins measured by targeted proteomics differ between rheumatoid arthritis patients, other inflammatory diseases, and healthy controls?
Population
RA patients (n = 46), other related inflammatory pathologies (n = 116), and controls (n = 62)
Comparison
RA vs other inflammatory pathologies vs controls
Design
Case-control study
Key result
SAA2 and S100A8/S100A9 proteins were significantly overexpressed in rheumatoid arthritis patients compared to controls, with SAA1 isoforms differentially present based on disease activity.
Authors
Loading...
SAA/S100 variant assay may aid RA biomarker research; hypothesis-generating and requires validation before clinical consideration.
Observational (n=224)
Do plasma levels of SAA variants and S100A8/S100A9 proteins measured by targeted proteomics differ between rheumatoid arthritis patients, other inflammatory diseases, and healthy controls?
Targeted proteomics reveals that specific SAA variants and S100A8/S100A9 proteins are differentially expressed in rheumatoid arthritis, suggesting their potential as biomarkers for disease activity and early onset.
Nys et al. (2019) conducted an observational in Rheumatoid arthritis (n=224). Rheumatoid arthritis and other inflammatory pathologies vs. Healthy controls was evaluated on Plasma levels of SAA variants and S100A8/S100A9 proteins. SAA2 and S100A8/S100A9 proteins were significantly overexpressed in rheumatoid arthritis patients compared to controls, with SAA1 isoforms differentially present based on disease activity.